Celularity Inc
CELU1.450USD
+0.200+16.00%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
40.91MMarket Cap
LossP/E TTM
More Details of Celularity Inc Company
Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.
Celularity Inc Info
Ticker SymbolCELU
Company nameCelularity Inc
IPO dateMay 23, 2019
CEOHariri (Robert J)
Number of employees123
Security typeOrdinary Share
Fiscal year-endMay 23
Address170 Park Ave
CityFLORHAM PARK
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code07932
Phone19087682170
Websitehttps://celularity.com/
Ticker SymbolCELU
IPO dateMay 23, 2019
CEOHariri (Robert J)
Company Executives of Celularity Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.11%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
3.70K
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John R. Haines
Mr. John R. Haines
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary
--
--
Mr. Joseph Dossantos
Mr. Joseph Dossantos
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Mr. Carlos Ramirez
Mr. Carlos Ramirez
Senior Vice President - Investor Relations
Senior Vice President - Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.86M
+0.11%
Mr. Vincent Levien
Mr. Vincent Levien
Independent Director
Independent Director
3.70K
--
Mr. Stephen A. Brigido
Mr. Stephen A. Brigido
President - Degenerative Disease
President - Degenerative Disease
--
--
Ms. Diane L. Parks
Ms. Diane L. Parks
Independent Director
Independent Director
--
--
Dr. Peter H. Diamandis, M.D.
Dr. Peter H. Diamandis, M.D.
Independent Director
Independent Director
--
--
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Genting Bhd
22.36%
Hariri (Robert J)
10.09%
Starr International Company, Inc.
5.39%
Lincoln Alternative Strategies LLC
4.34%
C.V. Starr & Co., Inc.
2.70%
Other
55.11%
Shareholders
Shareholders
Proportion
Genting Bhd
22.36%
Hariri (Robert J)
10.09%
Starr International Company, Inc.
5.39%
Lincoln Alternative Strategies LLC
4.34%
C.V. Starr & Co., Inc.
2.70%
Other
55.11%
Shareholder Types
Shareholders
Proportion
Corporation
26.71%
Individual Investor
12.96%
Investment Advisor
8.87%
Insurance Company
2.70%
Investment Advisor/Hedge Fund
1.32%
Hedge Fund
0.39%
Research Firm
0.19%
Family Office
0.04%
Other
46.82%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
71
3.82M
13.73%
--
2025Q3
80
3.82M
16.36%
+119.97K
2025Q2
92
3.70M
17.46%
+189.07K
2025Q1
120
3.51M
18.18%
-579.52K
2024Q4
135
3.39M
17.70%
+120.20K
2024Q3
149
3.27M
18.60%
+20.75K
2024Q2
160
3.32M
18.56%
+109.90K
2024Q1
166
3.20M
18.29%
-780.71K
2023Q4
164
3.20M
20.76%
-511.70K
2023Q3
164
3.71M
20.21%
+96.25K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Genting Bhd
6.34M
23.74%
--
--
Jul 24, 2025
Hariri (Robert J)
2.85M
10.7%
+3.28K
+0.12%
May 15, 2025
Starr International Company, Inc.
1.53M
5.73%
--
--
May 15, 2025
Lincoln Alternative Strategies LLC
1.23M
4.61%
+1.23M
--
Jul 14, 2025
C.V. Starr & Co., Inc.
764.07K
2.86%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
500.13K
1.87%
--
--
Jun 30, 2025
Diamandis (Peter)
134.31K
0.5%
-63.82K
-32.21%
May 15, 2025
Parks (Diane L.)
23.61K
0.09%
-67.42K
-74.06%
May 15, 2025
Geode Capital Management, L.L.C.
134.82K
0.51%
-1.22K
-0.89%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Date
Type
Ratio
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
Feb 23, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Celularity Inc?
The top five shareholders of Celularity Inc are:
Genting Bhd holds 6.34M shares, accounting for 23.74% of the total shares.
Hariri (Robert J) holds 2.85M shares, accounting for 10.70% of the total shares.
Starr International Company, Inc. holds 1.53M shares, accounting for 5.73% of the total shares.
Lincoln Alternative Strategies LLC holds 1.23M shares, accounting for 4.61% of the total shares.
C.V. Starr & Co., Inc. holds 764.07K shares, accounting for 2.86% of the total shares.
Genting Bhd holds 6.34M shares, accounting for 23.74% of the total shares.
Hariri (Robert J) holds 2.85M shares, accounting for 10.70% of the total shares.
Starr International Company, Inc. holds 1.53M shares, accounting for 5.73% of the total shares.
Lincoln Alternative Strategies LLC holds 1.23M shares, accounting for 4.61% of the total shares.
C.V. Starr & Co., Inc. holds 764.07K shares, accounting for 2.86% of the total shares.
What are the top three shareholder types of Celularity Inc?
The top three shareholder types of Celularity Inc are:
Genting Bhd
Hariri (Robert J)
Starr International Company, Inc.
Genting Bhd
Hariri (Robert J)
Starr International Company, Inc.
How many institutions hold shares of Celularity Inc (CELU)?
As of 2025Q4, 71 institutions hold shares of Celularity Inc, with a combined market value of approximately 3.82M, accounting for 13.73% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -2.64%.
What is the biggest source of revenue for Celularity Inc?
In --, the -- business generated the highest revenue for Celularity Inc, amounting to -- and accounting for --% of total revenue.
